Published in Circulation on November 17, 2009
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI2D) | NCT00006305
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. Diabetes Technol Ther (2015) 1.40
Risks and complications of coronary angiography: a comprehensive review. Glob J Health Sci (2012) 1.32
Third universal definition of myocardial infarction. Nat Rev Cardiol (2012) 1.12
Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2012) 1.04
PAI-1 and diabetes: a journey from the bench to the bedside. Diabetes Care (2012) 0.99
Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci (2011) 0.94
Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90
Coronary revascularization in diabetic patients: Current state of evidence. Exp Clin Cardiol (2011) 0.87
Qualitative assessment of neointimal tissue after drug-eluting stent implantation: comparison between follow-up optical coherence tomography and intravascular ultrasound. Am Heart J (2011) 0.86
Diabetic cardiovascular disease: getting to the heart of the matter. J Cardiovasc Transl Res (2012) 0.85
Prognostic value of automated vs visual analysis for adenosine stress myocardial perfusion SPECT in patients without prior coronary artery disease: a case-control study. J Nucl Cardiol (2011) 0.84
Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab (2013) 0.83
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Relationship between vascular stiffness and stress myocardial perfusion imaging in asymptomatic patients with diabetes. Eur J Nucl Med Mol Imaging (2011) 0.80
The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease. J Cardiovasc Magn Reson (2011) 0.79
Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol (2014) 0.77
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
Coronary artery disease and diabetes mellitus. Cardiol Clin (2014) 0.76
Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus. Curr Opin Pharmacol (2012) 0.75
Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. Ann Transl Med (2017) 0.75
Cardiovascular effects of basal insulins. Drug Healthc Patient Saf (2015) 0.75
Recent advances in the management of resistant hypertension. F1000Prime Rep (2015) 0.75
Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr (2017) 0.75
Prognostic relevance of PCI-related myocardial infarction. Nat Rev Cardiol (2013) 0.75
Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial. J Am Heart Assoc (2017) 0.75
Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study. Diabetol Metab Syndr (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Universal definition of myocardial infarction. Circulation (2007) 11.69
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) (2001) 8.45
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol (1986) 6.27
Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 3.17
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol (2009) 2.85
Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet (2009) 2.81
Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol (2003) 2.54
A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med (1985) 2.49
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med (2007) 2.12
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol (2009) 2.10
NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol (1992) 1.59
Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J (2008) 1.44
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv (2009) 1.38
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 1.37
Progression of proximal coronary artery lesions to total occlusion after aorta-coronary saphenous vein bypass grafting. J Thorac Cardiovasc Surg (1971) 1.27
Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab (1998) 1.26
Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 1.16
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes (2000) 1.14
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab (2001) 1.14
Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol (2001) 1.14
Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation (1999) 1.12
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Prospective, comprehensive assessment of cardiac troponin T testing after coronary artery bypass graft surgery. Circulation (2009) 1.08
Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care (2005) 1.02
Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg (2007) 1.02
Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Am J Cardiol (2009) 0.97
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J (2006) 0.92
Methodology of serial ECG classification using an adaptation of the NOVACODE for Q wave myocardial infarction in the Bypass Angioplasty Revascularization Investigation (BARI). J Electrocardiol (1996) 0.91
Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol (2006) 0.88
Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies. J Diabetes Complications (2002) 0.86
Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial. J Thorac Cardiovasc Surg (2003) 0.81
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Trial of Continuous or Interrupted Chest Compressions during CPR. N Engl J Med (2015) 6.66
Development and mapping of 2240 new SSR markers for rice (Oryza sativa L.). DNA Res (2002) 6.65
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med (2011) 3.76
Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA (2012) 3.66
Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA (2005) 3.51
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA (2004) 3.17
Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 2.95
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Ann Intern Med (2002) 2.87
Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg (2011) 2.85
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
Chest compression rates and survival following out-of-hospital cardiac arrest. Crit Care Med (2015) 2.77
Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med (2007) 2.70
Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol (2010) 2.68
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J (2006) 2.67
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol (2007) 2.49
Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 2.47
Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. N Engl J Med (2011) 2.45
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol (2010) 2.39
Immune activation of NF-kappaB and JNK requires Drosophila TAK1. J Biol Chem (2003) 2.38
Coronary heart disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol (2003) 2.34
Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.30
Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J Am Coll Cardiol (2010) 2.29
Relationship between chest compression rates and outcomes from cardiac arrest. Circulation (2012) 2.25
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation (2006) 2.24
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause (2011) 2.06
Navigating the crossroads of coronary artery disease and heart failure. Circulation (2006) 2.06
Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol (2002) 2.06
Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. Circulation (2004) 2.04
The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation (2006) 2.03
Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA (2010) 2.00
Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol (2008) 1.96
Temporal trends in the incidence of coronary disease. Am J Med (2004) 1.86
Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort study. Lancet (2002) 1.83
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: The prospective P2C2 HIV study. J Pediatr (2002) 1.80
Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res (2006) 1.77
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation (2011) 1.75
Screening for coronary artery disease in patients with diabetes. Diabetes Care (2007) 1.72
T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation (2002) 1.72
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol (2002) 1.64
Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: implications for clinical practice. Am Heart J (2003) 1.61
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Determination of menopausal status in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J Womens Health (Larchmt) (2004) 1.57
Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation (2010) 1.56
Yield of stress single-photon emission computed tomography in asymptomatic patients with diabetes. Am Heart J (2004) 1.55
Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol (2013) 1.55
Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol (2007) 1.53
The plant pathogen Pseudomonas syringae pv. tomato is genetically monomorphic and under strong selection to evade tomato immunity. PLoS Pathog (2011) 1.52
Strategies for recruitment and retention of participants in clinical trials. JAMA (2011) 1.51
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med (2006) 1.48
Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol (2006) 1.45
Toric Implantable Collamer Lens for moderate to high myopic astigmatism. Ophthalmology (2007) 1.45
The Imd pathway is involved in antiviral immune responses in Drosophila. PLoS One (2009) 1.44
Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol (2002) 1.44
Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol (2003) 1.44
Pulse pressure and adverse outcomes in women: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am J Hypertens (2008) 1.42
A graph-theoretic approach to comparing and integrating genetic, physical and sequence-based maps. Genetics (2003) 1.41
Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med (2007) 1.41
Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol (2013) 1.40
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
No scrubs in the ED. Aust Nurs J (2013) 1.39
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther (2005) 1.38
National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol (2010) 1.37
Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 1.37
Social networks are associated with lower mortality rates among women with suspected coronary disease: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation study. Psychosom Med (2004) 1.36
The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J (2009) 1.36
Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol (2006) 1.34
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J (2008) 1.33
Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv (2012) 1.30
Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J (2005) 1.30
Development and mapping of 2240 new SSR markers for rice (Oryza sativa L.) (supplement). DNA Res (2002) 1.29
Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation (2004) 1.28
Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol (2005) 1.27
Regulatory challenges for the resuscitation outcomes consortium. Circulation (2008) 1.26